BRPI0511782B8
(pt)
|
2004-06-03 |
2021-05-25 |
Novimmune Sa |
anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
|
CA2625440C
(en)
|
2005-10-11 |
2023-06-13 |
Micromet Ag |
Compositions comprising cross-species-specific antibodies and uses thereof
|
KR101589759B1
(ko)
*
|
2007-04-03 |
2016-01-29 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 cd3―입실론 결합 도메인
|
CA2682626A1
(en)
*
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
JP2010524851A
(ja)
†
|
2007-04-03 |
2010-07-22 |
マイクロメット アーゲー |
種間特異的結合ドメイン
|
US9260522B2
(en)
*
|
2008-10-01 |
2016-02-16 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
US10981998B2
(en)
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
NZ591134A
(en)
|
2008-10-01 |
2012-08-31 |
Micromet Ag |
Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa)
|
RU2547600C2
(ru)
|
2008-10-01 |
2015-04-10 |
Эмджен Рисерч (Мьюник) Гмбх |
Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
|
CN107227335A
(zh)
|
2009-10-27 |
2017-10-03 |
安进研发(慕尼黑)股份有限公司 |
用于施用CD19xCD3双特异性抗体的给药方案
|
MX338932B
(es)
*
|
2010-03-12 |
2016-05-06 |
Immunogen Inc |
Moleculas de union cd37 y sus inmunoconjugados.
|
TWI653333B
(zh)
*
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
EP2637670B2
(en)
|
2010-11-10 |
2024-03-13 |
Amgen Research (Munich) GmbH |
Prevention of adverse effects caused by cd3 specific binding domains
|
EP3974453A3
(en)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
US9249217B2
(en)
*
|
2010-12-03 |
2016-02-02 |
Secretary, DHHS |
Bispecific EGFRvIII x CD3 antibody engaging molecules
|
MX2013011385A
(es)
|
2011-04-01 |
2014-03-13 |
Immunogen Inc |
Moleculas de union a cd37 y sus inmunoconjugados.
|
CA2832360C
(en)
|
2011-04-28 |
2022-05-03 |
Amgen Research (Munich) Gmbh |
Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
|
US8846042B2
(en)
*
|
2011-05-16 |
2014-09-30 |
Fabion Pharmaceuticals, Inc. |
Multi-specific FAB fusion proteins and methods of use
|
UA117072C2
(uk)
|
2011-05-21 |
2018-06-11 |
Макродженікс, Інк. |
Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
US20130058937A1
(en)
|
2011-08-23 |
2013-03-07 |
Johannes Auer |
Bispecific antigen binding molecules
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
HUE038225T2
(hu)
|
2011-08-23 |
2018-10-29 |
Roche Glycart Ag |
Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
|
US11851476B2
(en)
|
2011-10-31 |
2023-12-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
TWI679212B
(zh)
*
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
AU2012350429A1
(en)
|
2011-12-09 |
2013-07-11 |
Amgen Research (Munich) Gmbh |
Prevention of adverse effects caused by EpCAMxCD3 bispecific antibodies
|
CA2864177C
(en)
*
|
2012-03-01 |
2019-11-26 |
Amgen Research (Munich) Gmbh |
Prolonged half-life albumin-binding protein fused bispecific antibodies
|
CN103382223B
(zh)
*
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
CA2876133C
(en)
*
|
2012-06-07 |
2017-06-06 |
Duke University |
Human bispecific egfrviii antibody engaging molecules
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
JOP20200236A1
(ar)
*
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
KR20150064068A
(ko)
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
CN104780940B
(zh)
|
2012-11-06 |
2017-11-07 |
拜耳制药股份公司 |
用于双特异性t细胞衔接体(bites)的制剂
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
*
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
PL2953972T3
(pl)
|
2013-02-05 |
2021-03-08 |
Engmab Sàrl |
Metoda wyboru przeciwciał przeciwko bcma
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
US9486475B2
(en)
|
2013-02-08 |
2016-11-08 |
Amgen Research (Munich) Gmbh |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP3444278A1
(en)
|
2013-02-26 |
2019-02-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
DK2961771T3
(da)
|
2013-02-26 |
2020-03-02 |
Roche Glycart Ag |
Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
ES2753950T3
(es)
|
2013-03-15 |
2020-04-15 |
Amgen Res Munich Gmbh |
Moléculas de unión monocatenarias que comprenden ABP del extremo N
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
SG11201509361TA
(en)
*
|
2013-05-28 |
2015-12-30 |
Numab Ag |
Novel antibodies
|
KR20230073341A
(ko)
|
2013-07-05 |
2023-05-25 |
젠맵 에이/에스 |
인간화 또는 키메라 cd3 항체
|
TR201904121T4
(tr)
*
|
2013-07-09 |
2019-04-22 |
The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human |
İnsan bispesifik egfrviii antikoru birleştirme molekülleri.
|
WO2015013671A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
JP6599338B2
(ja)
|
2013-09-16 |
2019-10-30 |
ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト(ゲーエムベーハー) |
Hbv感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびhbv抗原結合性の二重特異性または多重特異性ポリペプチド
|
CN113307873A
(zh)
|
2013-11-11 |
2021-08-27 |
中外制药株式会社 |
含有改变了抗体可变区的抗原结合分子
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
PL3192812T3
(pl)
|
2013-12-17 |
2020-10-19 |
Genentech, Inc. |
Przeciwciała anty-CD3 i sposoby ich zastosowania
|
WO2015105888A1
(en)
*
|
2014-01-07 |
2015-07-16 |
Bioatla, Llc |
Proteins targeting orthologs
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
LT3149480T
(lt)
|
2014-05-30 |
2019-04-25 |
Amgen Research (Munich) Gmbh |
B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
BR112016030740A2
(pt)
*
|
2014-07-01 |
2018-02-20 |
Pfizer Inc. |
diacorpos heterodiméricos biespecíficos e seus usos
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
US11820832B2
(en)
|
2014-07-25 |
2023-11-21 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
JP6871155B2
(ja)
|
2014-07-25 |
2021-05-12 |
メモリアル スローン ケタリング キャンサー センター |
二重特異性her2及びcd3結合分子
|
BR112017001579A2
(pt)
*
|
2014-07-25 |
2017-11-21 |
Cytomx Therapeutics Inc |
anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
|
AR101669A1
(es)
*
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
WO2016016415A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
WO2016020309A1
(en)
|
2014-08-04 |
2016-02-11 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
EP3204415B1
(en)
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
US10066002B2
(en)
|
2014-11-05 |
2018-09-04 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
AU2015342961B2
(en)
|
2014-11-05 |
2021-08-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
TWI831044B
(zh)
*
|
2014-11-11 |
2024-02-01 |
日商中外製藥股份有限公司 |
抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
|
EP3699198A1
(en)
|
2014-11-17 |
2020-08-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
MX2017006626A
(es)
|
2014-11-20 |
2017-08-21 |
Hoffmann La Roche |
Cadenas ligeras comunes y metodos de uso.
|
RS61134B1
(sr)
|
2014-11-20 |
2020-12-31 |
Hoffmann La Roche |
Kombinovana terapija bispecifičnim antigen vezujućim molekulima koji aktiviraju t ćelije za cd3 i folatni receptor 1 (folr1), i antagonistima vezivanja ose pd-1
|
PL3689140T3
(pl)
*
|
2014-11-24 |
2022-09-05 |
Regeneron Pharmaceuticals, Inc. |
Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
EP4039710A3
(en)
*
|
2015-01-23 |
2022-10-19 |
Sanofi |
Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
|
MX2017013348A
(es)
|
2015-04-17 |
2018-08-01 |
Amgen Res Munich Gmbh |
Construcciones de anticuerpos biespecificos contra cdh3 y cd3.
|
JP2018520642A
(ja)
*
|
2015-05-01 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
マスク抗cd3抗体及びその使用方法
|
EP3298042A1
(en)
|
2015-05-20 |
2018-03-28 |
Amgen Research (Munich) GmbH |
B-cell depletion as a diagnostic marker
|
EP3302555A4
(en)
*
|
2015-05-29 |
2018-07-11 |
Amphivena Therapeutics, Inc. |
Methods of using bispecific cd33 and cd3 binding proteins
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
US20170000900A1
(en)
|
2015-06-08 |
2017-01-05 |
Immunogen, Inc. |
Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
|
IL256079B2
(en)
|
2015-06-16 |
2024-01-01 |
Genentech Inc |
Human antibodies with improved affinity to FCRH5 - and methods of use
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
IL310467A
(en)
|
2015-07-15 |
2024-03-01 |
Genmab As |
Human CD3 antibodies or chimeras
|
EP3322735A4
(en)
*
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT
|
CN106349391A
(zh)
*
|
2015-07-17 |
2017-01-25 |
中国科学院深圳先进技术研究院 |
Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用
|
TW202346349A
(zh)
*
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI796283B
(zh)
*
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
KR20180042271A
(ko)
|
2015-08-03 |
2018-04-25 |
잉맵 에스에이알엘 |
Bcma에 대응하는 단일클론 항체
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
AU2016308567B2
(en)
|
2015-08-17 |
2022-10-27 |
Janssen Biotech, Inc. |
Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof
|
WO2017040344A2
(en)
|
2015-08-28 |
2017-03-09 |
Amunix Operating Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
MA42706A
(fr)
|
2015-08-28 |
2021-04-14 |
Debiopharm Int Sa |
Anticorps et dosages pour la détection de cd37
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
|
WO2017055392A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
EA201891084A1
(ru)
|
2015-11-02 |
2019-10-31 |
|
Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
KR20180104635A
(ko)
|
2015-12-30 |
2018-09-21 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
EP3192810A1
(en)
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
MA43955B1
(fr)
|
2016-02-03 |
2022-02-28 |
Amgen Inc |
Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
|
EA039325B1
(ru)
*
|
2016-02-03 |
2022-01-13 |
Эмджен Рисерч (Мюник) Гмбх |
Конструкции биспецифических антител, связывающиеся с дпб3 (dll3) и кд3 (cd3)
|
EA039859B1
(ru)
*
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
CN114716557A
(zh)
*
|
2016-02-03 |
2022-07-08 |
安进研发(慕尼黑)股份有限公司 |
Psma和cd3双特异性t细胞接合抗体构建体
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド (エイチケイ) リミテッド |
多重特異性Fab融合タンパクおよびその使用
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
KR20190053835A
(ko)
|
2016-06-21 |
2019-05-20 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
WO2018052503A1
(en)
|
2016-09-14 |
2018-03-22 |
Teneobio, Inc. |
Cd3 binding antibodies
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
US11278629B2
(en)
|
2016-11-02 |
2022-03-22 |
Debiopharm International, S.A. |
Methods for improving anti-CD37 immunoconjugate therapy
|
MX2019004621A
(es)
|
2016-11-02 |
2019-11-28 |
Engmab Sarl |
Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
|
JP2020503260A
(ja)
|
2016-11-15 |
2020-01-30 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
TWI829628B
(zh)
|
2016-12-19 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
與靶向4-1bb (cd137)促效劑併用之組合療法
|
BR112019007267A2
(pt)
|
2016-12-20 |
2019-07-09 |
Hoffmann La Roche |
anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
|
JP7254699B2
(ja)
|
2016-12-21 |
2023-04-10 |
テネオバイオ, インコーポレイテッド |
抗bcma重鎖のみ抗体
|
IL267567B1
(en)
|
2016-12-22 |
2024-04-01 |
Daiichi Sankyo Co Ltd |
Anti-CD3 antibody - for use in treating or preventing cancer and molecules containing the antibody
|
US11046768B2
(en)
|
2017-01-27 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
JP2020515532A
(ja)
|
2017-03-29 |
2020-05-28 |
グリコトープ ゲーエムベーハー |
Muc1およびcd3に結合する多重特異的抗体構築物
|
CN110494452B
(zh)
|
2017-04-03 |
2023-08-25 |
豪夫迈·罗氏有限公司 |
结合steap-1的抗体
|
CA3060856A1
(en)
|
2017-05-05 |
2018-11-08 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
MX2019014274A
(es)
|
2017-06-02 |
2020-01-23 |
Hoffmann La Roche |
Metodo de tratamiento.
|
WO2018224441A1
(en)
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
KR20200018498A
(ko)
|
2017-06-20 |
2020-02-19 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
CN117567624A
(zh)
|
2017-06-20 |
2024-02-20 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
EP3642229A1
(en)
|
2017-06-21 |
2020-04-29 |
Gilead Sciences, Inc. |
Multispecific antibodies that target hiv gp120 and cd3
|
JP7474193B2
(ja)
*
|
2017-06-25 |
2024-04-24 |
システィミューン, インク. |
多重特異性抗体とその作製及び使用方法
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
EP3661954B1
(en)
|
2017-08-03 |
2022-02-09 |
Amgen Inc. |
Interleukin-21 muteins and methods of treatment
|
AU2018314236A1
(en)
|
2017-08-11 |
2020-03-19 |
Apterna Limited |
RNA aptamers against transferrin receptor (TfR)
|
US11472880B2
(en)
|
2017-08-14 |
2022-10-18 |
Morphosys Ag |
Humanized antibodies for CD3
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
AU2018328291B2
(en)
|
2017-09-08 |
2022-10-27 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
JP2020534811A
(ja)
*
|
2017-09-08 |
2020-12-03 |
マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. |
Fc領域を含有する条件的に活性化された結合部分
|
MX2020003087A
(es)
|
2017-09-21 |
2020-08-17 |
Wuxi Biologics Ireland Ltd |
Anticuerpos anti-cd3epsilon novedosos.
|
US11472889B2
(en)
|
2017-10-14 |
2022-10-18 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
KR20200084006A
(ko)
|
2017-11-01 |
2020-07-09 |
에프. 호프만-라 로슈 아게 |
표적화된 ox40 작용제를 사용하는 병용 요법
|
US10426424B2
(en)
|
2017-11-21 |
2019-10-01 |
General Electric Company |
System and method for generating and performing imaging protocol simulations
|
US11952422B2
(en)
|
2017-12-05 |
2024-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
|
BR112020011627A2
(pt)
|
2017-12-11 |
2020-11-17 |
Amgen Inc. |
processo de fabricação contínuo para produtos de anticorpos biespecíficos
|
TWI805665B
(zh)
|
2017-12-21 |
2023-06-21 |
瑞士商赫孚孟拉羅股份公司 |
結合hla-a2/wt1之抗體
|
US11873336B2
(en)
|
2017-12-22 |
2024-01-16 |
Teneobio, Inc. |
Heavy chain antibodies binding to CD22
|
BR112020012591A2
(pt)
|
2017-12-22 |
2020-11-24 |
Genentech, Inc. |
células hospedeiras de integração direcionada (ti), células hospedeiras ti, métodos para preparar uma célula hospedeira ti, métodos para expressar um polipeptídeo de interesse e vetores
|
UY38041A
(es)
*
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
CR20210319A
(es)
|
2018-01-12 |
2021-07-27 |
Amgen Inc |
ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
WO2019149715A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Stabilized immunoglobulin domains
|
JP7475275B2
(ja)
|
2018-02-08 |
2024-04-26 |
ジェネンテック, インコーポレイテッド |
二重特異性抗原結合分子及びその使用方法
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
CN111655731A
(zh)
|
2018-03-13 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
KR20200132913A
(ko)
|
2018-03-13 |
2020-11-25 |
에프. 호프만-라 로슈 아게 |
4-1bb 작용제와 항-cd20 항체의 치료 조합
|
WO2019191552A1
(en)
|
2018-03-29 |
2019-10-03 |
Genentech, Inc. |
Modulating lactogenic activity in mammalian cells
|
BR112020020854A2
(pt)
|
2018-04-12 |
2021-01-19 |
Amgen Inc. |
Métodos para produzir composições de proteínas estáveis
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
DK3794042T3
(da)
|
2018-05-18 |
2024-04-15 |
Daiichi Sankyo Co Ltd |
Anti-muc1-exatecet-antistof-lægemiddelkonjugat
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
CA3098420A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
AU2019281358A1
(en)
|
2018-06-03 |
2021-01-07 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against CEACAM5 and CD47
|
TW202021616A
(zh)
|
2018-07-30 |
2020-06-16 |
美商安進公司 |
結合至cd33和cd3的雙特異性抗體構建體之延長投與
|
TW202019477A
(zh)
|
2018-07-31 |
2020-06-01 |
德商安美基研究(慕尼黑)公司 |
BCMAxCD3抗體構建體之給藥方案
|
MX2021001353A
(es)
|
2018-08-03 |
2021-04-13 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3.
|
JP2021535142A
(ja)
|
2018-08-31 |
2021-12-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Cd3/c20二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略
|
CA3111462A1
(en)
|
2018-09-11 |
2020-03-19 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Improved anti-flt3 antigen binding proteins
|
EP3623383A1
(en)
|
2018-09-11 |
2020-03-18 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Improved bispecific flt3xcd3 antigen binding proteins
|
AR114732A1
(es)
|
2018-09-18 |
2020-10-07 |
Hoffmann La Roche |
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
EP3856781A1
(en)
|
2018-09-28 |
2021-08-04 |
Amgen Inc. |
Antibodies against soluble bcma
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
US20210340273A1
(en)
|
2018-10-11 |
2021-11-04 |
Inhlbrx, inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
US20210380679A1
(en)
|
2018-10-11 |
2021-12-09 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
US20210395298A1
(en)
|
2018-10-11 |
2021-12-23 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
WO2020076970A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
CA3115296A1
(en)
|
2018-10-23 |
2020-04-30 |
Amgen Inc. |
Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
CA3117051A1
(en)
|
2018-11-05 |
2020-05-14 |
Genentech, Inc. |
Methods of producing two chain proteins in prokaryotic host cells
|
US20200179500A1
(en)
*
|
2018-12-05 |
2020-06-11 |
Wayne State University |
Methods and immunogenic compositions relating to her2 with selective sequence modifications
|
CN113631711A
(zh)
|
2018-12-21 |
2021-11-09 |
豪夫迈·罗氏有限公司 |
核酸的靶向整合
|
SG10202105788SA
(en)
|
2018-12-21 |
2021-06-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
BR112021014481A2
(pt)
|
2019-01-23 |
2021-10-13 |
Genentech, Inc. |
Método para produzir um polipeptídeo multimérico, método para produzir um anticorpo biespecífico, pluralidade de polipeptídeos multiméricos, células hospedeiras eucarióticas recombinantes, método para identificar uma combinação de sequências e kit de polinucleotídeos
|
TW202043253A
(zh)
|
2019-01-28 |
2020-12-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
CN114390938A
(zh)
|
2019-03-05 |
2022-04-22 |
武田药品工业有限公司 |
受约束的条件性活化的结合蛋白
|
CN114423499A
(zh)
*
|
2019-06-06 |
2022-04-29 |
佳努克斯治疗公司 |
与肿瘤激活的t细胞衔接子相关的组合物和方法
|
JP2022535060A
(ja)
|
2019-06-07 |
2022-08-04 |
アムジエン・インコーポレーテツド |
選択的に切断可能なリンカーを有する二重特異性結合構築物
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
AR119746A1
(es)
|
2019-06-14 |
2022-01-05 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
WO2021050640A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
US20230136228A1
(en)
|
2019-09-18 |
2023-05-04 |
Lamkap Bio Alpha AG |
Bispecific antibodies against ceacam5 and cd3
|
MX2022003212A
(es)
|
2019-09-18 |
2022-04-25 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
|
AU2020358022A1
(en)
|
2019-10-03 |
2022-03-31 |
Amgen Inc. |
Method for conducting solid state NMR on macromolecule-containing solid state formulations
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
EP4054590A1
(en)
|
2019-11-04 |
2022-09-14 |
Amgen Inc. |
Methods for treating leukemia
|
EP3819312A1
(en)
|
2019-11-10 |
2021-05-12 |
Amgen, Inc |
Dosing regimen for anti-dll3 agents
|
EP3819007A1
(en)
|
2019-11-11 |
2021-05-12 |
Amgen Research (Munich) GmbH |
Dosing regimen for anti-bcma agents
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
US20230000916A1
(en)
*
|
2019-11-27 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Anti-cd3 scfv and cytokine producing artificial antigen presenting cells
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
CA3163950A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
JP7296467B2
(ja)
|
2019-12-18 |
2023-06-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hla-a2/mage-a4に結合する抗体
|
CA3164129A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
EP4081294A2
(en)
|
2019-12-23 |
2022-11-02 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
CN115315446A
(zh)
|
2020-03-06 |
2022-11-08 |
Go医疗股份有限公司 |
抗糖-cd44抗体及其用途
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
KR20220159426A
(ko)
|
2020-03-26 |
2022-12-02 |
제넨테크, 인크. |
감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
|
CN115397866A
(zh)
|
2020-03-31 |
2022-11-25 |
中外制药株式会社 |
靶向dll3的多特异性抗原结合分子及其用途
|
IL296664A
(en)
|
2020-04-24 |
2022-11-01 |
Hoffmann La Roche |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
CN115894703A
(zh)
|
2020-04-29 |
2023-04-04 |
特尼奥生物股份有限公司 |
具有经修饰重链恒定区的多特异性重链抗体
|
JP2023524068A
(ja)
|
2020-04-30 |
2023-06-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
サイトカイン関連有害事象を治療する方法
|
WO2021224913A1
(en)
|
2020-05-04 |
2021-11-11 |
Immunorizon Ltd. |
Precursor tri-specific antibody constructs and methods of use thereof
|
CN116249548A
(zh)
|
2020-05-11 |
2023-06-09 |
詹森生物科技公司 |
用于治疗多发性骨髓瘤的方法
|
EP4153633A1
(en)
|
2020-05-19 |
2023-03-29 |
Amgen Inc. |
Mageb2 binding constructs
|
MX2022014902A
(es)
|
2020-05-29 |
2023-01-04 |
Amgen Inc |
Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3.
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
MX2022015206A
(es)
|
2020-06-08 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso.
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
CN115916825A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与cd3和cd19结合的抗体
|
CN115916826A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与CD3和FolR1结合的抗体
|
CN115698084A
(zh)
|
2020-06-19 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
EP4172192A1
(en)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
IL299120A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
A targeted combination of nucleic acids
|
JP2023534458A
(ja)
|
2020-07-17 |
2023-08-09 |
ジェネンテック, インコーポレイテッド |
抗Notch2抗体及び使用方法
|
CN114057882B
(zh)
*
|
2020-07-31 |
2023-01-06 |
山东博安生物技术股份有限公司 |
多价多特异性抗体
|
CA3190797A1
(en)
|
2020-08-10 |
2022-02-17 |
Julius-Maximilians-Universitat Wurzburg |
Siglec-6-binding polypeptides
|
US11512113B2
(en)
|
2020-08-11 |
2022-11-29 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
US20240092931A1
(en)
*
|
2020-08-24 |
2024-03-21 |
Janux Therapeutics, Inc. |
Antibodies targeting trop2 and cd3 and uses thereof
|
KR20230056766A
(ko)
|
2020-08-28 |
2023-04-27 |
제넨테크, 인크. |
숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
|
EP4210747A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
WO2022053656A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー/エス |
濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
|
JP2023541858A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー/エス |
慢性リンパ球性白血病を治療するためのcd3及びcd20に対する二重特異性抗体
|
WO2022053657A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
EP4210748A1
(en)
|
2020-09-11 |
2023-07-19 |
Amgen Inc. |
Materials and methods to reduce protein aggregation
|
AU2021345124A1
(en)
|
2020-09-16 |
2023-03-30 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
CN116209680A
(zh)
|
2020-09-24 |
2023-06-02 |
莫佛塞斯公司 |
与人CD3ε结合的新型人抗体
|
US20220168407A1
(en)
|
2020-11-05 |
2022-06-02 |
Dcprime B.V. |
Use of tumor-independent antigens in immunotherapies
|
TW202233678A
(zh)
|
2020-11-06 |
2022-09-01 |
德商安美基研究(慕尼黑)公司 |
具有增強的剪切特徵的多肽
|
CN116323671A
(zh)
|
2020-11-06 |
2023-06-23 |
安进公司 |
具有增加的选择性的多靶向性双特异性抗原结合分子
|
BR112023008629A2
(pt)
|
2020-11-06 |
2023-10-03 |
Amgen Inc |
Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3
|
BR112023008670A2
(pt)
|
2020-11-06 |
2024-02-06 |
Amgen Inc |
Construtos polipeptídicos ligados à cd3
|
TW202233682A
(zh)
|
2020-11-10 |
2022-09-01 |
美商安進公司 |
用於投與BCMAxCD3結合分子之方法
|
EP4255931A1
(en)
|
2020-12-03 |
2023-10-11 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
KR20230135575A
(ko)
|
2020-12-09 |
2023-09-25 |
재눅스 테라퓨틱스 인크. |
Psma 및 이펙터 세포 항원을 표적화하는 종양 활성화항체와 관련된 조성물 및 방법
|
IL303656A
(en)
|
2020-12-17 |
2023-08-01 |
Hoffmann La Roche |
ANTI-HLA-G antibodies and their use
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
JP2024505600A
(ja)
|
2021-02-03 |
2024-02-06 |
モーツァルト セラピューティクス, インコーポレイテッド |
結合剤およびそれを使用する方法
|
US20220267438A1
(en)
|
2021-02-16 |
2022-08-25 |
Janssen Pharmaceutica Nv |
Trispecific antibody targeting bcma, gprc5d, and cd3
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
抗グリコcd44抗体およびその使用
|
CN116997357A
(zh)
|
2021-03-08 |
2023-11-03 |
免疫医疗有限责任公司 |
针对gdf-15的抗体
|
WO2022191971A1
(en)
|
2021-03-10 |
2022-09-15 |
Amgen Inc. |
Parallel chromatography systems and methods
|
JP2024509877A
(ja)
|
2021-03-10 |
2024-03-05 |
アムジエン・インコーポレーテツド |
組換えタンパク質の精製方法
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
BR112023019484A2
(pt)
|
2021-03-24 |
2023-12-05 |
Janssen Biotech Inc |
Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
|
WO2022212831A1
(en)
|
2021-04-02 |
2022-10-06 |
Amgen Inc. |
Mageb2 binding constructs
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
CA3215965A1
(en)
|
2021-04-19 |
2022-10-27 |
Amy Shen |
Modified mammalian cells
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
CN117279947A
(zh)
|
2021-05-06 |
2023-12-22 |
安进研发(慕尼黑)股份有限公司 |
用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
CN115536740A
(zh)
*
|
2021-06-30 |
2022-12-30 |
苏州方德门达新药开发有限公司 |
介导细胞内有效滞留cd3的空间构象表位及其应用
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
US20230197278A1
(en)
|
2021-07-13 |
2023-06-22 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
KR20240036570A
(ko)
|
2021-07-22 |
2024-03-20 |
에프. 호프만-라 로슈 아게 |
이종이량체 Fc 도메인 항체
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
CA3228178A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
AU2022339667A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
TW202325733A
(zh)
|
2021-09-03 |
2023-07-01 |
美商Go治療公司 |
抗醣化-lamp1抗體及其用途
|
WO2023057571A1
(en)
|
2021-10-08 |
2023-04-13 |
Genmab A/S |
Antibodies binding to cd30 and cd3
|
CA3235228A1
(en)
|
2021-10-15 |
2023-04-20 |
Amgen Research (Munich) Gmbh |
Subcutaneous administration of cd19-binding t cell engagers
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
TW202326113A
(zh)
|
2021-10-27 |
2023-07-01 |
美商安進公司 |
使用光譜學進行的基於深度學習的預測
|
AU2022382368A1
(en)
|
2021-11-03 |
2024-05-02 |
Affimed Gmbh |
Bispecific cd16a binders
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023110918A1
(en)
|
2021-12-14 |
2023-06-22 |
Cdr-Life Ag |
Dual mhc-targeting t cell engager
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
WO2023164474A1
(en)
|
2022-02-23 |
2023-08-31 |
Amgen Inc. |
Cancer treatment targeting dll3
|
WO2023183231A1
(en)
|
2022-03-21 |
2023-09-28 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023178645A1
(zh)
*
|
2022-03-25 |
2023-09-28 |
嘉和生物药业有限公司 |
靶向cd3的抗体及其应用
|
TW202346337A
(zh)
|
2022-03-29 |
2023-12-01 |
美商恩格姆生物製藥公司 |
Ilt3及cd3結合劑以及其使用方法
|
JP2024517042A
(ja)
|
2022-04-13 |
2024-04-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
US20240091262A1
(en)
|
2022-09-14 |
2024-03-21 |
Cdr-Life Ag |
Mage-a4 peptide dual t cell engagers
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024081918A1
(en)
|
2022-10-14 |
2024-04-18 |
Talem Therapeutics Llc |
Anti-trkb/cd3 antibodies and uses thereof
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|